These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37322038)

  • 21. Parkinson disease and incidental Lewy body disease: Just a question of time?
    Iacono D; Geraci-Erck M; Rabin ML; Adler CH; Serrano G; Beach TG; Kurlan R
    Neurology; 2015 Nov; 85(19):1670-9. PubMed ID: 26468408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder.
    Valli M; Cho SS; Uribe C; Masellis M; Chen R; Mihaescu A; Strafella AP
    Mol Brain; 2021 Nov; 14(1):165. PubMed ID: 34758845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?
    Frigerio R; Fujishiro H; Ahn TB; Josephs KA; Maraganore DM; DelleDonne A; Parisi JE; Klos KJ; Boeve BF; Dickson DW; Ahlskog JE
    Neurobiol Aging; 2011 May; 32(5):857-63. PubMed ID: 19560232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.
    Wilson JM; Levey AI; Rajput A; Ang L; Guttman M; Shannak K; Niznik HB; Hornykiewicz O; Pifl C; Kish SJ
    Neurology; 1996 Sep; 47(3):718-26. PubMed ID: 8797470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
    J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic exposure to dopamine agonists affects the integrity of striatal D
    Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
    Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders.
    Caviness JN; Adler CH; Hentz JG; Shill HA; Evidente VG; Driver-Dunckley ED; Sabbagh MN; Sue L; Beach TG
    Clin Neurophysiol; 2011 Dec; 122(12):2426-32. PubMed ID: 21616709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.
    Milber JM; Noorigian JV; Morley JF; Petrovitch H; White L; Ross GW; Duda JE
    Neurology; 2012 Dec; 79(24):2307-14. PubMed ID: 23152586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic Neuroleptic-Induced Parkinsonism Examined With Positron Emission Tomography.
    Galoppin M; Berroir P; Soucy JP; Suzuki Y; Lavigne GJ; Gagnon JF; Montplaisir JY; Stip E; Blanchet PJ
    Mov Disord; 2020 Jul; 35(7):1189-1198. PubMed ID: 32353194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
    Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
    Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography.
    Lehéricy S; Brandel JP; Hirsch EC; Anglade P; Villares J; Scherman D; Duyckaerts C; Javoy-Agid F; Agid Y
    Brain Res; 1994 Oct; 659(1-2):1-9. PubMed ID: 7820649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
    Colloby SJ; McParland S; O'Brien JT; Attems J
    Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K; Schwarz J; Mozley PD; Linke R; Pogarell O; Oertel WH; Fieber RS; Hahn K; Kung HF
    Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.